Here is the Bristol-Myers Squibb release -- and here is the Kenilworth version. A bit then, from each follows:
. . . .[BMS] today announced that it received the Prix Galien USA 2015 Award for Best Biotechnology Product for Opdivo® (nivolumab), the Company’s PD-1 immune checkpoint inhibitor. Bristol-Myers Squibb was recognized for its innovative discovery and development of Opdivo in approved indications for previously treated metastatic squamous non-small cell lung cancer (NSCLC), and in unresectable or metastatic melanoma. . . .
[Merck] today announced that Keytruda® (pembrolizumab), the company’s anti-PD-1 therapy for the treatment of advanced melanoma and metastatic non-small cell lung cancer in patients whose disease has progressed after other therapies, received the Prix Galien USA 2015 Award for Best Biotechnology Product.
"As a company built on a foundation of scientific excellence, Merck is honored to again have been chosen as a recipient of this prestigious award," said Dr. Roger M. Perlmutter, president, Merck Research Laboratories. "This achievement is a testament to the remarkable contributions of everyone at Merck, as well as the many physicians and patients who participated in our clinical trials, in helping to bring KEYTRUDA to patients". . . .
So. . . Kudos, all around! Onward, and keep it spinning in life affirming good karma, one and all! Namaste!
No comments:
Post a Comment